XTRA:RDCConsumer Retailing
Redcare Pharmacy (XTRA:RDC) Stock Could Be 76% Below Fair Value After Guidance Upgrade
Guidance upgrade puts Redcare Pharmacy stock back in focus
Redcare Pharmacy (XTRA:RDC) raised its full year 2026 guidance after reporting stronger than expected Q2 2026 trading, highlighting faster year on year growth in prescription and non prescription sales, especially in Germany.
The company now targets total revenue growth of 15% to 17% for 2026, compared with a previous range of 13% to 15%, and guides for an adjusted EBITDA margin between 2.5% and 3.0%.
See our latest analysis for...